Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA117849 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Androgen receptor RIP-seq of LNCaP cells treated with androgen hormone
| PRJNA392760 | ENA
Project description:Gene expression data from treated LNCaP prostate cells.
| PRJNA136509 | ENA
Project description:Androgen-starved LNCaP cells treated with celastrol and androgen, androgen alone, or vehicle alone for 24h
| PRJNA96159 | ENA
Project description:Androgen-starved LNCaP cells treated with gedunin and androgen, androgen alone, or vehicle alone for 24h
| PRJNA96161 | ENA
Project description:Expression data from LNCaP prostate cancer cells treated with taxanes
| PRJNA268012 | ENA
Project description:Expression data from LNCaP cells treated with DHT and enzalutamide
| PRJNA192516 | ENA
Project description:We report the androgen receptor recruitment to the chromatin of androgen responsive prostate cancer cell lines, LNCaP-1F5 and VCaP in response to physiological androgen 5a-dihydrotestosterone (DHT) using ChIP-sequencing. We compare the AR recruitment by DHT to that by partial agonist/antagonist cyproterone acetate (CPA), mifepristone (RU486) and bicalutamide (Bica) in LNCaP-1F5 cells. We also report the role of glucocorticoid receptor recruitment in presence of dexamethasone (Dex) in androgen responsive prostate cancer cells. The AR and GR cistrome analysis is subsequently compared with gene expression data and RNA Pol II analysis. The ChIP-seq has been performed using AR, GR, RNA Pol II antibodies. Examination of AR and GR binding sites in LNCaP-1F5 and VCaP cells in presence of DHT and Dex respectively. Further analysis of AR binding sites in LNCaP-1F5 cells treated with partial agonist/antagonists, CPA, RU486 and Bica. Additionally RNA Pol II mapping is performed in cells treated with DHT and Dex.
2013-02-05 | E-GEOD-39879 | biostudies-arrayexpress
Project description:In this study the development of androgen independence in a cell model of disease was selected as a mirror of to the events at play in the development of Castrate Resistant Prostate Cancer in-vivo. LNCaP cells which are androgen dependent and androgen independent sublines; LNCaP-Abl and LNCaP-Abl-Hof were subject to extensive fractionation by 1-D SDS PAGE and accurate mass-high resolution mass spectrometry (Q Exactive) to identify proteins whose expression was changes significantly in response to androgen independent growth.
2022-02-28 | PXD000751 | Pride